Epioxa is the first epithelium-on cross-linking procedure approved in the U.S. Glaukos plans for Epioxa to be commercially ...

Epioxa does not require the removal of the corneal epithelium, a step usually required by traditional corneal cross-linking procedures, thereby minimizing pain and recovery time.

Glaukos announced that the FDA has approved the new drug application for its topical drug therapy (Epioxa HD/Epioxa) for ...

The US Food and Drug Administration (FDA) has approved Glaukos Corporation’s Epioxa, offering patients living with a rare ...

Epithelium-on cross-linking with oxygen supplementation showed efficacy, safety and speed as a treatment for keratoconus, according to a poster presentation. At the American Academy of Ophthalmology ...

Glaukos recently obtained FDA clearance for Epioxa, a topical, incision-free therapy for keratoconus that preserves the ...

Glaukos (NYSE:GKOS) announced today that the FDA approved its Epoxia incision-free alternative to corneal cross-linking ...

Glaukos’ Epioxa allows cross-linking therapy for keratoconus without requiring an incision. The biotech expects to launch the ...

The FDA approval of Epioxa is based on results from two prospective, randomized, multicenter, double-masked, Phase 3 pivotal trials that randomized a total of over 400 patients. Both trials ...

Glaukos plans to file for US approval of its iLink corneal cross-linking therapy Epioxa (Epi-on) for treating keratoconus after the therapy met the primary endpoint in a Phase III trial. The study met ...

Understanding Keratoconus and Corneal Cross Linking Mass Appeal / May 16, 2025 / 02:14 PM EDT If you've been diagnosed with Keratoconus then Corneal Cross Linking might get you back to better eyesight ...

Researchers receive £2.4 million to advance a minimally invasive treatment for keratoconus, aiming to reduce NHS costs ...